Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque ...

Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...

Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between ...

The Motley Fool. DATE Wednesday, July 16, 2025 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — ...

While Stelara is used in fewer indications than Humira, it commands a large market share in its therapeutic areas, most ...

Ulcerative colitis (UC) causes misery for millions worldwide. It affects the large intestine, causing pain, cramping, and ...

Greater access to innovative treatments could be linked to a drop in patients requiring surgery for a type of inflammatory ...

Arthritis is often associated with older adults, but children can develop it, too. Known as juvenile arthritis, this group of conditions can affect a child’s joints, immune system, and overall health.

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

Over the coming years, the Inflation Reduction Act aims to help those with Medicare save on their prescription drug costs. Learn more.

Over the coming years, the Inflation Reduction Act aims to save people with Medicare money on their prescription medications. Read more.

The U.S. FDA has accepted a Biologics License Application (BLA) for BAT2506, a proposed biosimilar to Simponi (golimumab).